Company news

Agios Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

June 20, 2021

Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent α- and β-Thalassemia at the European Hematology Association Virtual Congress

June 10, 2021

Agios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at the European Hematology Association Virtual Congress

June 10, 2021

Agios to Present Updated Data from Clinical Trials of Mitapivat in Pyruvate Kinase Deficiency and Thalassemia in Oral Presentations at the European Hematology Association Annual Congress

May 11, 2021

Agios Reports Business Highlights and First Quarter 2021 Financial Results

April 28, 2021

Agios to Webcast Conference Call of First Quarter 2021 Financial Results on April 29, 2021

April 14, 2021

Agios Announces Closing of Oncology Business Sale to Servier

March 31, 2021

Agios Shareholders Approve Sale of Oncology Business to Servier

March 24, 2021

Agios Sponsors Program Promoting Health Literacy for Patients with Sickle Cell Disease

March 17, 2021

Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

February 28, 2021

Agios Recognizes 14th Annual Rare Disease Day and Raises Awareness of Unmet Needs in Rare Hemolytic Anemias

February 25, 2021

Agios Reports Fourth Quarter and Full Year 2020 Financial Results

February 24, 2021

Agios to Present at March Investor Conferences

February 22, 2021

Agios to Webcast Conference Call of Fourth Quarter and Year End 2020 Financial Results on February 25, 2021

February 10, 2021

Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused

January 25, 2021

Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

January 16, 2021

Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation

January 10, 2021

Agios to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021

January 4, 2021

Agios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2 Billion Plus Royalties

December 20, 2020

Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease

December 6, 2020

Agios Announces the Phase 3 ACTIVATE Trial of Mitapivat Achieved Its Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused

November 30, 2020

Agios Launches Anemia ID, a No-Cost Genetic Testing Program for Hereditary Anemias

November 29, 2020

Agios to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020

November 24, 2020

Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease

November 11, 2020

Agios Reports Business Highlights and Third Quarter 2020 Financial Results

November 4, 2020

Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the Virtual 2020 ASH Annual Meeting

November 3, 2020

Agios to Host a Webinar on its Pyruvate Kinase-R (PKR) Activation Clinical Programs and Commercial Outlook on Thursday, November 19, 2020

October 28, 2020

Agios to Webcast Conference Call of Third Quarter 2020 Financial Results on November 5, 2020

October 21, 2020

Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia

October 15, 2020

Agios Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients

September 20, 2020

Agios Appoints Jonathan Biller as Chief Financial Officer, Head of Legal and Corporate Affairs

September 7, 2020

Agios to Present at the Citi 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020

August 26, 2020

Agios to Present at the Virtual Canaccord 40th Annual Growth Conference on Thursday, August 13, 2020

August 5, 2020

Agios Reports Business Highlights and Second Quarter 2020 Financial Results

July 29, 2020

Agios to Webcast Conference Call of Second Quarter 2020 Financial Results on July 30, 2020

July 15, 2020

Agios to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference on Tuesday, June 23, 2020

June 16, 2020

Agios First-in Class PKR Activator Mitapivat Demonstrates Sustained Hemoglobin Responses in Non-transfusion-dependent α- and β-Thalassemia in Phase 2 Study

June 11, 2020

Agios Announces Clinical Proof-of-Concept Has Been Established in Phase 1 Study of Mitapivat, First-in Class PKR Activator, in Sickle Cell Disease

June 11, 2020

Agios and Royalty Pharma Announce $255 Million Purchase Agreement for IDHIFA® Royalty

June 11, 2020

Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Thalassemia

June 7, 2020

Agios Presents Updated Data from the Phase 1 Dose-escalation Study of Vorasidenib in Patients with IDH-mutant Non-enhancing Glioma

May 28, 2020

Agios Announces Publication of TIBSOVO® Phase 3 Data in The Lancet Oncology Demonstrating Significant Improvement in Progression-Free Survival Compared to Placebo in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients

May 18, 2020

Agios to Present Updated Clinical Proof-of-Concept Data from the Phase 2 Study of Mitapivat in Thalassemia in Oral Presentation at the European Hematology Association Annual Congress

May 13, 2020

Agios to Present Updated Data from the Phase 1 Study of Vorasidenib in Non-enhancing Glioma in Oral Presentation at the American Society of Clinical Oncology Annual Meeting

May 12, 2020

Agios to Present at the RBC Capital Markets Global Healthcare Virtual Conference on Tuesday, May 19, 2020

May 11, 2020

Agios Reports First Quarter 2020 Financial Results and Provides Update on Business Operations and COVID-19 Response

April 29, 2020

Agios to Webcast Conference Call of First Quarter 2020 Financial Results on April 30, 2020

April 15, 2020

Agios Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Mitapivat in Pyruvate Kinase Deficiency

March 29, 2020

Agios Provides Update on 2016 Collaboration Agreement with Celgene, a Wholly Owned Subsidiary of Bristol Myers Squibb

March 24, 2020

Agios Announces FDA Clearance of Investigational New Drug Application for AG-946, a Next-Generation PKR Activator

March 22, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 26 calls. Every call is listed under its year.

Decks

The 5 newest of 37 decks. Every deck is listed under its year.